AUTL Share Price Performance
US$1.44
0.11 (8.27%)
83.7% undervalued intrinsic discount
US$8.81
Fair Value
Price US$1.44
AnalystConsensusTarget US$8.81
AnalystHighTarget US$13.00
AnalystLowTarget US$5.00
Fair ValueUS$8.81
Share Pricen/a
Autolus Therapeutics plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 24 Fair Values set on narratives written by author
AUTL Community Narratives
AN
Fair Value
·Fair Value US$8.81 83.7% undervalued intrinsic discount
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
1users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
Fair Value
·Fair Value US$13 88.9% undervalued intrinsic discount
Cell Therapy Platforms Will Meet Rising Demand From Aging Populations
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$5 71.2% undervalued intrinsic discount
High Costs And Delays Will Challenge Therapy Rollout With Promise
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Robust Clinical Uptake Will Expand Advanced Cancer Therapy Adoption
Key Takeaways Accelerating adoption, regulatory progress, and expanded clinical indications position Autolus for increased market share and long-term revenue growth in advanced cancer therapies. Improved manufacturing efficiency and financial discipline strengthen margins, enabling investment in innovation and geographic expansion while supporting sustained profitability.Read more
AN
US$8.81
83.7% undervalued intrinsic discount
Fair Value
Profit Margin
14.82%
Future PE
60.2x
Price in 2029
US$11.46
Cell Therapy Platforms Will Meet Rising Demand From Aging Populations
Key Takeaways Rapidly accelerating AUCATZYL adoption and advanced manufacturing could drive stronger revenue growth and operating leverage than analysts expect. Robust long-term demand and untapped expansion into new indications position Autolus for sustained revenue growth and strategic partnership opportunities.Read more
AN
US$13
88.9% undervalued intrinsic discount
Fair Value
Profit Margin
9.28%
Future PE
83.45x
Price in 2028
US$16.45
High Costs And Delays Will Challenge Therapy Rollout With Promise
Key Takeaways Delayed European access, high costs, and heavy reliance on the U.S. market threaten top-line growth and prolong the path to profitability. Pipeline concentration, steep R&D spend, and rising competition increase earnings risk and may limit international and long-term revenue potential.Read more
AN
US$5
71.2% undervalued intrinsic discount
Fair Value
Profit Margin
16.25%
Future PE
81.93x
Price in 2028
US$6.33
Trending Discussion
Recently Updated Narratives
AN
AUTL: Higher Risk Assumptions Will Still Support Upside Potential
Fair Value: US$8.81 83.7% undervalued intrinsic discount
10 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
High Costs And Delays Will Challenge Therapy Rollout With Promise
Fair Value: US$5 71.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Cell Therapy Platforms Will Meet Rising Demand From Aging Populations
Fair Value: US$13 88.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Autolus Therapeutics plc Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.08
- -175.09%
- -381.40%
- 151.7%
About AUTL
- Founded
- 2014
- Employees
- 753
- CEO
- WebsiteView website
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
